A widely used supplement for joint pain relief, glucosamine, may be linked to faster progression of Alzheimer’s disease, according to new research from the University of Florida. The study suggests that individuals with mild cognitive impairment who take glucosamine are more likely to develop dementia, and it raises concerns about the supplement’s potential impact on those already diagnosed with the disease.
Key Takeaways
- Glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia.
- Among patients diagnosed with Alzheimer’s disease and related dementias, glucosamine use correlated with a 25% increase in mortality risk.
- Researchers suggest glucosamine may be harmful to a brain already affected by neurodegeneration, but potentially safe or protective in cognitively healthy adults.
- The findings highlight the role of metabolic dysfunction in Alzheimer’s progression.
Glucosamine Use and Dementia Risk
Researchers analyzed deidentified health records from the University of Florida Health system, focusing on patients diagnosed with Alzheimer’s disease and related dementias (ADRD) or mild cognitive impairment (MCI). The study found that approximately 8% of patients in both groups reported taking glucosamine. After accounting for factors like age and sex, the analysis revealed that glucosamine users with MCI were 25% more likely to develop dementia. Furthermore, among patients already diagnosed with ADRD, glucosamine use was associated with a 25% increase in mortality risk over a 10-year period. Notably, no similar increase in mortality was observed in the MCI group, suggesting the supplement’s effects may differ based on disease stage.
Potential Biological Mechanisms
The study also explored potential biological explanations for the observed association. Researchers identified evidence of an overactive protein and sugar-tagging pathway in Alzheimer’s disease, which could serve as a new target for treatments. Glucosamine, a molecule that can cross the blood-brain barrier, may interact with these metabolic processes. Experiments in genetically modified mice showed that glucosamine increased the attachment of sugar molecules to proteins, leading to worsened social memory deficits. Conversely, reducing this sugar-tagging activity improved memory performance in the mice. Analysis of human brain tissue from Alzheimer’s patients also revealed significantly higher levels of sugar attachment to proteins compared to healthy controls.
Implications and Future Directions
While the findings are observational and require confirmation through clinical trials, they add to the growing evidence that metabolic dysfunction plays a significant role in neurodegenerative diseases. Experts emphasize that the supplement appears safe or potentially protective for cognitively healthy adults, but may be harmful once neurodegeneration has begun. The research team plans further studies, including trials to assess whether discontinuing glucosamine slows cognitive decline in affected individuals and to screen compounds that could block the problematic sugar-tagging pathway. They also intend to investigate whether other supplements processed similarly to glucosamine carry comparable risks.
Sources
- Popular joint supplement glucosamine linked to faster Alzheimer’s progression, ScienceDaily.
- Study links joint pain supplement to accelerating dementia, UF Health.
- Popular Supplement Linked to Faster Alzheimer’s Progression, Newsweek.
- Alzheimer’s May Be Worse for People Taking Popular Supplement, MedPage Today.
- Glucosamine supplements may speed memory loss from Alzheimer’s, new research shows, The Conversation.